Professor Suzanne Chambers AO is a health psychologist and registered nurse who has been working as a practitioner-researcher in psycho-oncology for over 30 years. She was awarded her PhD in 2004 within the School of Psychology at Griffith University and has over 300 peer reviewed publications and numerous books, book chapters and monographs. Her work has focussed on developing models to predict help seeking and adjustment after cancer: designing remote access psychological interventions for people affected by cancer; integrating peer support into controlled design methodologies; integrating distress screening into interventions to target high distress cancer patient groups. She is currently the Executive Dean of Health Sciences at the Australian Catholic University.

I am an Associate Attending Behavioral Scientist in the Department of Psychiatry and Behavioral Sciences at MSKCC. I received my PhD in Health Communication in 2005 from Rutgers University, under the mentorship of Dr. Kathryn Greene. My research is in cancer prevention and control, with special emphasis on the role of communication between oncology health care providers (HCPs) and patients, and message framing for cancer risk prevention. My recent work has primarily been contextualized in the areas of communication skills training to (a) improve sexual and gender minority (SGM) sensitivity for oncology HCPs, (b) reduce stigma experienced by patients with lung cancer who smoke(d), and (c) encourage HCPs to discuss sexual health concerns of cisgender female patients with cancer. My research has been funded by the NCI, NIDA, and philanthropic organizations like T. J. Martell Foundation, Goldstein Foundation, and Geri & Me Foundation. I have published over 85 peer-reviewed manuscripts, 15 reviews and book chapters, and presented in over 100 national and international conferences.

I am a clinical health psychologist with expertise in helping patients and their families cope with the challenges of cancer diagnosis, treatment, and survivorship. I have a strong interest in working with patients who have been diagnosed with tobacco-related cancers, and I serve as psychological liaison to the Thoracic Service and to the Head and Neck Disease Management Team. I am the Director of Memorial Sloan Kettering's Tobacco Treatment Program and work with a team of colleagues dedicated to promoting smoking cessation among cancer patients, their families, and individuals at risk for cancer and other chronic medical conditions.
I also lead the Health Behavior Change and Cancer Risk Reduction Laboratory examining psychological and behavioral factors in cancer prevention and early detection. My research has focused on developing and evaluating innovative methods for treating tobacco dependence in medical settings. My other research interests include post-treatment, health-related quality of life issues and the development and evaluation of psychosocial support and health promotion interventions for cancer survivors and their families.
Additionally, I serve as Director of the Psycho-Oncology Research Training Program and am strongly committed to training new investigators in psycho-oncology. I serve on many academic and national committees aimed at improving cancer prevention, early detection, and care.

Dr. Jamie L. Studts is a Professor of Medical Oncology at the University of Colorado School of Medicine and Scientific Director of Behavioral Oncology. Dr. Studts also serves as the Co-Leader for the Cancer Prevention and Control program and Co-Director of the Population Health Shared Resource at the University of Colorado Cancer Center. Prior to joining the University of Colorado, Dr. Studts served as Professor of Behavioral Science at the University of Kentucky College of Medicine, Assistant Director for Cancer Prevention and Control, and Director of the Behavioral and Community-Based Research Shared Resource Facility at the University of Kentucky Markey Cancer Center. Dr. Studts is a licensed clinical health psychologist, and his interests address behavioral aspects of tobacco-related malignancies. His research develops and tests interventions to promote informed/shared decision making and behavior change among patients and clinicians regarding prevention, screening, and survivorship of lung and head/neck cancer. His research has been funded by NCI, NIDCR, NIDA, NIEHS, the Bristol-Myers Squibb Foundation, and the Kentucky Lung Cancer Research Program. Dr. Studts is the Principal Investigator of the Kentucky LEADS Collaborative, and he previously served on the Institute of Medicine National Cancer Policy Forum addressing Implementation of Lung Cancer Screening. He is a Fellow of the Society of Behavioral Medicine, a member of the Scientific Leadership Board for the GO2 Foundation for Lung Cancer, and the National Comprehensive Cancer Network’s Lung Cancer Screening and Smoking Cessation Guideline Panels. Dr. Studts serves as a member of the Steering Committee for the American Cancer Society’s National Lung Cancer Roundtable and Chairs the Survivorship, Stigma, and Nihilism Task Group. Recently, Dr. Studts joined the Steering Committee for the Lung Ambition Alliance. In 2019 he received the Centerstone Healthcare Advocacy award in recognition of his efforts to reduce the burden of lung cancer in Kentucky.

PhD in Medical Physics from University of Chicago. As faculty in radiation oncology at University of Rochester between 1992-1998, Physics Division Head in Radiation Oncology at Henry Ford Hospital between 1998-2004, and Professor and Director of Radiation Physics in radiation oncology at Duke University health System since 2004.

Dept. Radiology
Shanghai Changzheng Hospital, China
Associate chief physician, Master’s supervisor
Focus on Chest imaging, especially lung cancer screening and COPD
Academic position：
Secretary, ASTR
Vice president, Youth Committee of Chinese Society of Radiology
Vice president, Youth Committee of Shanghai Society of Radiology
Committee member, Respiratory Committee of Chinese Association of Radiologists

Dr. Sales dos Santos has a Medical degree from the Federal University of Bahia in Brazil, surgical residency at the State University of Campinas, Sao Paulo, Brazil, and also research and clinical fellowships in general thoracic surgery and lung transplantation at the Allegheny General Hospital and University of Pittsburgh Medical Center (Pennsylvania, USA) from 2002 to 2007. He was an Instructor in Minimally Invasive CT surgery at Boston Medical Center, and faculty at the Boston University School of Medicine (BUSM, Massachusetts, USA) from 2007 to 2009.
Since 2010 Dr. Sales dos Santos has worked as a thoracic surgeon at Hospital Israelita Albert Einstein. Among his attributions he collaborated with the development of the Minimally Invasive Thoracic Surgery Program, EBUS and the Lung Cancer Screening Study (BRELT1-Propulmão). Currently, He is also a board member of the “ProAr Foundation”, of the IASLC's Early Detection Committee and a Visiting Professor at SENAI Cimatec University Center in Bahia, Brazil, where he is developing the next phase of “Propulmão”: a pioneer initiative on Lung Cancer Screening and treatment in Brazil.

Ugo Pastorino is Director of the Thoracic Surgery Division at the Istituto Nazionale Tumori of Milan (INTM) since 2003. Graduated in Medicine in 1979 at the University of Milan and specialised in Emergency Surgery, Oncology and Thoracic Surgery. In 1991 launched the International Registry of Lung Metastases. From 1982 to 1988 acted as Executive Director of the European School of Oncology (ESO). Appointed as consultant thoracic surgeon at the Royal Brompton Hospital of London in 1994, Head of Thoracic Surgery at the European Institute of Oncology (IEO) from 1998, and Scientific Director of INTM in 2014/2015. From 2001 to 2014 was Associate Editor of the Journal of the National Cancer Institute. Author of 393 papers, with an H-index of 62 (Scopus), is actually the PI of three prospective trials on lung cancer screening with LDCT and circulating biomarkers (MILD, BioMILD, SMILE). In 2016 he received the Joseph Cullen Award for Research on Lung Cancer Prevention from the IASLC.

Ichiro Yoshino, M.D., Ph.D. is chairman and professor of department of general thoracic surgery, Chiba University Graduate School of Medicine, and chief of general thoracic surgery, Chiba University Hospital, Japan. Prof. Yoshino currently serves as the president of Japanese Association for Chest Surgery, and the secretary general of Japanese Joint Committee of Lung Cancer Registry, that has been contributed to TNM revision of IASLC/AJCC. He is also involved in nation-wide clinical trials concerning lung cancer surgery and perioperative multimodal treatments. He has more than 300 scientific articles and one of opinion readers in Japan.